Market revenue in 2020 | USD 2,699.2 million |
Market revenue in 2028 | USD 4,805.2 million |
Growth rate | 7.5% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | Neurodegenerative Diseases |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 45.54% in 2020. Horizon Databook has segmented the Spain central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
Spain has a high incidence of both anxiety and depression, with 6 out of every 10 Spaniards showing symptoms of these disorders. Moreover, the country faces a severe shortage of psychologists, with only ~ 3 psychologists per 100,000 of the population.
As a result, for management of mental health conditions, prescription drugs are always the first option. In addition, Spain has a dementia prevalence rate of 4% to 9%, in the population aged over 65 years. According to the Alzheimer’s Association ~800,000 individuals are believed to be living with dementia and Alzheimer’s in the country.
To counter this problem, a National Plan has been launched by the government in 2019, with the aim of improving awareness to promote research in the field. Moreover, it is forecasted that nearly 1 million people in the country will be affected by dementia by 2030, due to aging.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into Spain central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account